Tscan Therapeutics Inc (NASDAQ: TCRX) on Thursday, soared 10.77% from the previous trading day, before settling in for the closing price of $1.30. Within the past 52 weeks, TCRX’s price has moved between $1.02 and $9.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 167.40%. The company achieved an average annual earnings per share of -14.36%. With a float of $43.27 million, this company’s outstanding shares have now reached $52.31 million.
Considering the fact that the conglomerate employs 194 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 15.84%, operating margin of -4787.68%, and the pretax margin is -4527.66%.
Tscan Therapeutics Inc (TCRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tscan Therapeutics Inc is 23.53%, while institutional ownership is 69.40%. The most recent insider transaction that took place on Dec 13 ’24, was worth 290,140. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $2.90, taking the stock ownership to the 5,357,347 shares. Before that another transaction happened on Dec 12 ’24, when Company’s 10% Owner bought 31,800 for $3.01, making the entire transaction worth $95,629. This insider now owns 5,257,347 shares in total.
Tscan Therapeutics Inc (TCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.58% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Tscan Therapeutics Inc (TCRX) is currently performing well based on its current performance indicators. A quick ratio of 8.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.25 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Compared to the last year’s volume of 0.42 million, its volume of 0.5 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 77.95%. Additionally, its Average True Range was 0.17.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 10.71%, which indicates a significant decrease from 77.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.35% in the past 14 days, which was higher than the 92.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7085, while its 200-day Moving Average is $4.0810. Nevertheless, the first resistance level for the watch stands at $1.5700 in the near term. At $1.7000, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8400. If the price goes on to break the first support level at $1.3000, it is likely to go to the next support level at $1.1600. Now, if the price goes above the second support level, the third support stands at $1.0300.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
Market capitalization of the company is 81.49 million based on 56,591K outstanding shares. Right now, sales total 2,820 K and income totals -127,500 K. The company made 670 K in profit during its latest quarter, and -35,810 K in sales during its previous quarter.
